ALPN vs. ALKS, MDGL, NUVL, PRGO, OGN, BBIO, INSM, PBH, RARE, and CRNX
Should you be buying Alpine Immune Sciences stock or one of its competitors? The main competitors of Alpine Immune Sciences include Alkermes (ALKS), Madrigal Pharmaceuticals (MDGL), Nuvalent (NUVL), Perrigo (PRGO), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Insmed (INSM), Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical preparations" industry.
Alpine Immune Sciences (NASDAQ:ALPN) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.
Alpine Immune Sciences presently has a consensus price target of $50.33, suggesting a potential downside of 22.08%. Alkermes has a consensus price target of $35.38, suggesting a potential upside of 46.18%. Given Alkermes' stronger consensus rating and higher probable upside, analysts clearly believe Alkermes is more favorable than Alpine Immune Sciences.
Alpine Immune Sciences has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Alkermes has higher revenue and earnings than Alpine Immune Sciences. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Alkermes received 306 more outperform votes than Alpine Immune Sciences when rated by MarketBeat users. Likewise, 70.69% of users gave Alkermes an outperform vote while only 64.57% of users gave Alpine Immune Sciences an outperform vote.
75.2% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 42.3% of Alpine Immune Sciences shares are owned by company insiders. Comparatively, 4.9% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Alkermes had 20 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 22 mentions for Alkermes and 2 mentions for Alpine Immune Sciences. Alpine Immune Sciences' average media sentiment score of 0.72 beat Alkermes' score of 0.24 indicating that Alpine Immune Sciences is being referred to more favorably in the media.
Alkermes has a net margin of 25.17% compared to Alpine Immune Sciences' net margin of -54.66%. Alkermes' return on equity of 20.31% beat Alpine Immune Sciences' return on equity.
Summary
Alkermes beats Alpine Immune Sciences on 14 of the 18 factors compared between the two stocks.
Get Alpine Immune Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpine Immune Sciences Competitors List
Related Companies and Tools
